Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Estriol→

Estriol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-27-1
Molecular formula
C18H24O3
Molecular weight
288.4 g/mol
Drug class
Weak natural oestrogenestrogen receptor agonist
Mechanism of action
Activates estrogen receptors, inducing transcription of oestrogen-responsive genes. Estriol has lower potency and shorter receptor interaction than estradiol and is used largely in local genitourinary formulations.
Indications / reported uses
  • Local treatment of symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women with authorised vaginal cream, pessary or tablet formulations
  • Systemic hormone replacement use is jurisdiction- and product-specific and should not be inferred from local vaginal preparations

Sources: UK product information — Estriol vaginal products · NLM MeSH — Estriol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Estriol Environmental Risk Assessment (ERA) (the Estriol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.